Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…Abstract Number: 1560 • ACR Convergence 2024
Changes of Cerebral Structure and Perfusion Vary in Different Subtypes of Systemic Sclerosis: A Brain Magnetic Resonance Imaging Study
Background/Purpose: The characteristics of brain impairment in different subtypes of systemic sclerosis (SSc) (dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous SSc) remain unclear. This study aimed to characterize cerebral structure and perfusion…Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…Abstract Number: 1823 • ACR Convergence 2024
Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts
Background/Purpose: Systemic Sclerosis (SSc) is a molecularly heterogeneous disease. Distinct subtypes of patients have been identified based on gene expression in skin. In this study,…Abstract Number: 2206 • ACR Convergence 2024
There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients
Background/Purpose: In adult systemic sclerosis they are significant differences in clinical presentation of diffuse and limited subtype. In juvenile systemic sclerosis (jSSc) are the differences less…Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…Abstract Number: 0405 • ACR Convergence 2023
Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study
Background/Purpose: Anti-Th/To antibodies (Abs) have been reported in patients with systemic sclerosis (SSc). The presence of anti-Th/To Abs is detected in 2-5% of SSc cases…Abstract Number: 0626 • ACR Convergence 2023
Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study
Background/Purpose: Anti-human upstream-binding factor (hUBF) antibodies (Abs) have been reported predominantly in patients with connective tissue diseases (CTDs) but have also been reported in non-CTDs…Abstract Number: 0648 • ACR Convergence 2023
Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort
Background/Purpose: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc), and may lead to malnutrition that adversely affects quality of life, morbidity and…Abstract Number: 0669 • ACR Convergence 2023
Optical Coherence Tomography Angiography in Systemic Sclerosis: Correlations with Morphological and Functional Peripheral Microvascular Status
Background/Purpose: Systemic sclerosis (SSc) is a rare and complex autoimmune disease featured by a progressive microvascular damage. The involvement of the ocular microvasculature has been…Abstract Number: 0943 • ACR Convergence 2023
Attenuation of Fibroblast Activation and Fibrosis by Adropin in a Hedgehog-Dependent Manner
Background/Purpose: Adropin is a secretory protein encoded by the energy homeostasis - associated (ENHO) gene. Emerging evidence indicate its role in metabolism and energy homeostasis,…Abstract Number: 1216 • ACR Convergence 2023
“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune rheumatic disease with heterogeneous manifestations, including common symptoms such as pain, fatigue, dyspnea, and Raynaud's phenomenon. It…Abstract Number: 1663 • ACR Convergence 2023
Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells
Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…Abstract Number: 2356 • ACR Convergence 2023
A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by inflammation and fibrosis. Treatment with mycophenolate mofetil (MMF), an inhibitor of lymphocyte…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 56
- Next Page »
